Clinical Evaluation of the Accuracy of Vitastiq Device for Tracking Vitamin and Mineral Trend in Human Body

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-17

Study Completion Date

2017-11-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single site evaluation study of Vitastiq device accuracy in healthy men and women in ratio 1:1 (approximately) aged between 18 and 64 years. A total of 45 Vitastiq personal devices will be used by volunteers for two months. The Vitastiq device will be evaluated during three site visits: on day 1, 29 ± 4 days and 57 ± 4 days. During site visit days, blood sampling will be collected and analysed and readings using Vitastiq device will be performed. Data will be analysed retrospectively to evaluate Vitastiq performance compared to blood tests results.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH Cartridge

NCT06352125

Surgery

COMPLETED

Validation of Point of Care Liver Function Tests

NCT03800069

Liver Diseases Healthy Cirrhosis, Liver +1 more

TERMINATED

Using SCOUT Noninvasive AGE Measurements to Forecast Diabetes Complications

NCT01415115

Type 1 Diabetes Type 2 Diabetes

COMPLETED

Tolerance and Practicality of Module AOX

NCT00425529

Gastrointestinal Diseases Nutrition

COMPLETED EARLY_PHASE1

Evaluate Retention of an Orally Administered Device Using Gamma Scintigraphy

NCT00754091

Healthy Subjects

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

No Conditions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitastiq device

Vitastiq device is used for about 2 months to perform Vitastiq readings every day, preferably in the morning.

Group Type EXPERIMENTAL

Vitasitiq device

Intervention Type DEVICE

Participant uses Vitastiq device for about 2 months to perform Vitastiq readings every day, preferably in the morning. On day 1, 29 and 57 participants' blood sampling is collected and analysed, and measurements using Vitastiq device are performed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitasitiq device

Participant uses Vitastiq device for about 2 months to perform Vitastiq readings every day, preferably in the morning. On day 1, 29 and 57 participants' blood sampling is collected and analysed, and measurements using Vitastiq device are performed.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent form (ICF) is signed by a volunteer
* Age between 18 and 64 years at the time of the signature of ICF
* A body mass index (BMI) between 18 and 28 kg/m2
* Healthy, meaning absence of any chronic or acute medical therapy for a month prior to the inclusion to the study
* Willing to follow all study procedures, including attending all site visits, and keeping a food diary and diary of activities on a weekly basis

Exclusion Criteria

* Intake of any drugs to treat chronic disease within 1 month before the beginning and during the study
* Intake of any drugs to treat serious acute disease within 1 month before the beginning of the study and within 5 days of each visit
* Any clinically significant medical history of serious digestive tract, liver, kidney, skin or haematological disease or hormone imbalance
* Pregnant and breastfeeding women
* Women who planning pregnancy during the study
* Inadequate veins (in the opinion of the investigator)
* Known drug or alcohol abuse
* Using any form of nicotine or tobacco
* Mental incapacity that precludes adequate understanding or cooperation
* Participation in another investigational study or blood donation within 3 months prior to or during this study

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes